Skip to main content

Table 5 Subgroup analysis of efficacy and safety according to tumor type and ICI therapy

From: Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection

Tumor Types

(N)

Co-infection

(N)

Anti-PD-(L)1 Monotherapy

Anti-PD-(L)1 plus Chemotherapy

ORRa

N (%)

Any grade irAEs N (%)

Grade ≥ 3 irAEs N (%)

ORR

N (%)

Any grade irAEs N (%)

Grade ≥ 3 irAEs N (%)

NSCLC (22)

HIV (12)

1(13)

2(25)

2(25)

3(75)

1(25)

0

HBV/HCV(10)

1(14)

4(57)

2(29)

2(67)

1(33)

1(33)

HCC (17)

HBV/HCV(16)

3(19)

7(44) b

4(25)b

 
  1. aResponse evaluable patients
  2. bTwo patients with baseline grade ≥ 2 hepatitis
Back to article page